MA42420A - Vaccins pour le traitement et la prévention du cancer - Google Patents

Vaccins pour le traitement et la prévention du cancer

Info

Publication number
MA42420A
MA42420A MA042420A MA42420A MA42420A MA 42420 A MA42420 A MA 42420A MA 042420 A MA042420 A MA 042420A MA 42420 A MA42420 A MA 42420A MA 42420 A MA42420 A MA 42420A
Authority
MA
Morocco
Prior art keywords
vaccines
cancer
prevention
treatment
Prior art date
Application number
MA042420A
Other languages
English (en)
Inventor
Jennifer Shanda Buell
John Christopher Castle
Daniel Lewis Levey
Robert Benjamin Stein
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of MA42420A publication Critical patent/MA42420A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001107—Fibroblast growth factor receptors [FGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001108—Platelet-derived growth factor receptors [PDGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA042420A 2015-05-13 2016-05-13 Vaccins pour le traitement et la prévention du cancer MA42420A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562161053P 2015-05-13 2015-05-13
US201562205591P 2015-08-14 2015-08-14
US201562257458P 2015-11-19 2015-11-19
US201662307592P 2016-03-14 2016-03-14

Publications (1)

Publication Number Publication Date
MA42420A true MA42420A (fr) 2018-05-23

Family

ID=56072474

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042420A MA42420A (fr) 2015-05-13 2016-05-13 Vaccins pour le traitement et la prévention du cancer

Country Status (14)

Country Link
US (2) US10568948B2 (fr)
EP (1) EP3294324A1 (fr)
JP (2) JP6925980B2 (fr)
KR (1) KR20180006945A (fr)
CN (1) CN107847572A (fr)
AU (2) AU2016260540B2 (fr)
CA (1) CA2984643A1 (fr)
EA (1) EA201792501A1 (fr)
HK (1) HK1252873A1 (fr)
IL (2) IL293135A (fr)
MA (1) MA42420A (fr)
MX (2) MX392028B (fr)
SG (1) SG10201912485PA (fr)
WO (1) WO2016183486A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3294324A1 (fr) * 2015-05-13 2018-03-21 Agenus Inc. Vaccins pour le traitement et la prévention du cancer
EP3364949A4 (fr) 2015-10-22 2019-07-31 ModernaTX, Inc. Vaccins anticancéreux
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
CN109923121B (zh) * 2016-11-22 2022-12-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc. anticorpos anti-cd137 e métodos de uso dos mesmos
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
KR20200003917A (ko) * 2017-05-10 2020-01-10 난토믹스, 엘엘씨 암의 검출, 예측, 및 모니터링을 위한 순환 rna(circulating rna for detection, prediction, and monitoring of cancer)
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
EP3784688A2 (fr) 2018-04-26 2021-03-03 Agenus Inc. Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
US20210268086A1 (en) * 2018-06-27 2021-09-02 Modernatx, Inc. Personalized cancer vaccine epitope selection
EP3618071A1 (fr) * 2018-08-28 2020-03-04 CeCaVa GmbH & Co. KG Procédés de sélection de néo-antigènes spécifiques de tumeur
CN113039612A (zh) * 2018-08-28 2021-06-25 赛科维有限两合公司 分级和/或选择肿瘤特异性新抗原的方法
CN110917341A (zh) * 2018-09-20 2020-03-27 天津贝罗尼生物科技有限公司 一种小鼠肿瘤疫苗及其制备方法
BR112021005702A8 (pt) * 2018-09-27 2022-11-08 Vaccibody As Método para selecionar neoepítopos
CN109438570B (zh) * 2018-11-28 2021-07-20 生命谷（海南）生物科技股份有限公司 肿瘤相关基因fgfr3突变短肽及其应用
CN109517053B (zh) * 2018-11-28 2021-10-08 生命谷（海南）生物科技股份有限公司 肿瘤相关基因ret突变短肽及其应用
CN112687354B (zh) * 2019-01-29 2022-07-12 杭州纽安津生物科技有限公司 针对靶向药物PI3K、AKT、mTOR通路的激酶抑制剂的多肽疫苗组合及其设计方法
WO2020221783A1 (fr) * 2019-04-29 2020-11-05 Vaccibody As Procédés de présélection de néo-épitopes
AU2020315981A1 (en) * 2019-07-24 2022-02-17 Agenus Inc. Antigenic polypeptides and methods of use thereof
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
WO2021205027A1 (fr) 2020-04-09 2021-10-14 Vaccibody As Vaccin anticancéreux thérapeutique individualisé
CN112002374B (zh) * 2020-06-14 2022-04-22 北京臻知医学科技有限责任公司 基于深度学习的mhc-i表位亲和力预测方法
JP7829242B2 (ja) * 2020-11-20 2026-03-13 シンク・セラピューティクス・インコーポレイテッド 最適化ペプチドワクチンの組成物および方法
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
WO2022115415A1 (fr) * 2020-11-24 2022-06-02 Providence Health & Services - Oregon Récepteurs de lymphocytes t spécifiques d'une forme mutante de l'oncogène ret et leurs utilisations
CN112608992B (zh) * 2020-12-21 2022-05-10 黄志玲 一种msh6突变基因及其应用
CN113173985A (zh) * 2021-03-24 2021-07-27 深圳市新靶向生物科技有限公司 一种与结直肠癌驱动基因突变相关的抗原肽及其应用
CN114163510B (zh) * 2021-03-24 2024-12-06 深圳市新靶向生物科技有限公司 一种与肝癌驱动基因突变相关的抗原肽组合及其应用
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
EP4569140A1 (fr) * 2022-08-12 2025-06-18 Amazon Technologies, Inc. Identification des cellules tumorales par mise en correspondance des mutations dans les séquences d'adn en masse avec les séquences d'adn monocellulaire
WO2024054892A1 (fr) * 2022-09-09 2024-03-14 Shape Therapeutics Inc. Peptides thérapeutiques

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4761470A (en) 1985-12-16 1988-08-02 Merck & Co., Inc. Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5137819A (en) 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
GB8915019D0 (en) 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
JPH07505719A (ja) 1992-04-14 1995-06-22 デューク・ユニバーシティー ｐ５３及びＨＳＰ７０のコンプレックスを含む腫瘍の検出方法
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
ATE198277T1 (de) 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5496934A (en) 1993-04-14 1996-03-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acids encoding a cellulose binding domain
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
JP4163253B2 (ja) 1995-08-18 2008-10-08 スローン−ケッタリング インスティチュート フォー キャンサー リサーチ 熱ショックタンパク質に基づくワクチンおよび免疫療法
EP0851765A4 (fr) 1995-09-13 2000-01-19 Univ Fordham Procedes therapeutique et profilactique utilisant des proteines du choque thermique
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
DE19602985A1 (de) 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AU4502797A (en) 1996-10-01 1998-04-24 Dana-Farber Cancer Institute Immunological therapy for cancer
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
ES2265165T3 (es) 1997-07-10 2007-02-01 Mannkind Corporation Dispositivo para inducir una respuesta ltc.
EP0893507A1 (fr) 1997-07-25 1999-01-27 Institut Gustave Roussy Utilisation de ligands de MHC classe II (CD4 et LAG-3) comme adjuvants pour la vaccination de LAG-3 dans le traitement du cancer
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
EP1030819A4 (fr) 1997-09-30 2001-11-21 Cel Sci Corp Polypeptide immunogenique conjugue destine au traitement du virus herpes simplex
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
WO1999022761A1 (fr) 1997-10-31 1999-05-14 Sloan-Kettering Institute For Cancer Research Peptides conjugues se liant aux proteines du stress
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
JP2002506633A (ja) 1998-03-20 2002-03-05 ジェンザイム・コーポレーション Ｔ細胞応答を誘発するための遺伝子に基づくワクチンの組成物および使用法
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
ATE315405T1 (de) 1998-08-10 2006-02-15 Antigenics Inc Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
KR100731820B1 (ko) 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
EP1126872B1 (fr) 1998-10-29 2006-12-13 Dana-Farber Cancer Institute, Inc. IMMUNOTHERAPIE ET DIAGNOSTIC DU CANCER AU MOYEN D'ANTIGENES UNIVERSELS ASSOCIES A DES TUMEURS TELS QUE hTERT
WO2001022972A2 (fr) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Acides nucleiques immunostimulateurs
CA2397374A1 (fr) 2000-01-13 2001-07-19 Antigenics Inc. Compositions de stimulation de l'immunite naturelle a base de cpg et de saponine et procedes correspondants
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US20010034042A1 (en) 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
GB0004547D0 (en) 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
WO2001079259A1 (fr) 2000-04-17 2001-10-25 Rothman James E Complexation d'antigenes proteiques et de proteines de stress par sequence javelot
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
HK1079705A1 (zh) 2001-08-20 2006-04-13 University Of Connecticut Health Center 包含用於治疗癌症及感染性疾病的热休克蛋白或α2-巨球蛋白的组合物制备方法
US20040071656A1 (en) * 2001-12-26 2004-04-15 Felix Wieland Modulation of heat-shock-protein-based immunotherapies
US7026167B2 (en) 2001-12-28 2006-04-11 University Of Virginia Patent Foundation Systems and methods for the analysis of protein phosphorylation
EP1578773A3 (fr) 2002-02-28 2005-12-14 Antigenics Inc. Methodes fondees sur l'oligomerisation de proteines de stress et produits associes
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
AU2003231098A1 (en) 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
CN1665533A (zh) 2002-05-02 2005-09-07 康涅狄格大学健康中心 热激蛋白用于增强抗体疗法功效的用途
US20050221350A1 (en) 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
WO2004033657A2 (fr) 2002-10-07 2004-04-22 Antigenics, Inc. Fragments de cd91 de liaison a des proteines de choc thermique et utilisations de ceux-ci
US7420037B2 (en) * 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
WO2004074454A2 (fr) 2003-02-20 2004-09-02 University Of Connecticut Health Center Methodes et compositions de traitement du cancer et de maladies infectieuses utilisant des complexes de molecules antigenes d'alpha (2) macroglobuline
JP2006514088A (ja) 2003-02-20 2006-04-27 ユニバーシティー オブ コネティカット ヘルス センター 癌および感染症の治療における熱ショックタンパク質またはα−２−マクログロブリンを含む組成物の使用方法
CN1816348A (zh) * 2003-04-11 2006-08-09 抗基因公司 改良的基于热休克蛋白的疫苗和免疫治疗
WO2004091493A2 (fr) 2003-04-11 2004-10-28 Antigenics, Inc. Vaccins ameliores a base de proteines de choc thermique et immunotherapies associees
US7309491B2 (en) 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
JP2007519910A (ja) 2004-01-28 2007-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドの同定および定量方法
CA2603191A1 (fr) 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Vaccins contre le cancer et methodes therapeutiques
US8663645B2 (en) 2005-05-09 2014-03-04 Vaxon Biotech Use of native peptides and their optimized derivatives for vaccination
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
JP2009532664A (ja) 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 癌の治療のためのノボペプチドの同定および使用
WO2008027800A2 (fr) 2006-08-29 2008-03-06 Temple University - Of The Commonwealth System Of Higher Education Méthode améliorant l'efficacité de l'immunothérapie antitumorale spécifique d'antigènes
AT504160A1 (de) 2006-09-11 2008-03-15 Ralf Dr Kircheis Verwendung einer mehrkomponenten-tumorvakzine
CA2665816C (fr) 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Vaccins a multiples epitopes specifiques a un antigene
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
CN101657213B (zh) 2007-02-15 2014-02-26 曼康公司 用于增强t细胞应答的方法
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
WO2009101205A2 (fr) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Lutte par voie immunogène contre les tumeurs et cellules tumorales
EP2113253B1 (fr) 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Nouvelles formules de peptides associées aux tumeurs à liaison aux molécules II ou I de classe d'antigène (HLA) de leucocyte humain pour vaccins
JP2009273377A (ja) 2008-05-12 2009-11-26 Igaku Seibutsugaku Kenkyusho:Kk Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法
AU2010232490B2 (en) 2009-04-03 2016-08-11 Agenus Inc. Methods for preparing and using multichaperone-antigen complexes
US10024868B2 (en) 2009-06-09 2018-07-17 Vaxon Biotech Identification, optimization and use of shared HLA-B*0702 epitopes for immunotherapy
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
KR20130113953A (ko) 2010-05-21 2013-10-16 유니버시티 오브 마이애미 암 치료
EP2576614A4 (fr) 2010-05-24 2013-11-13 Phosimmune Inc Phosphopeptides du cmh de classe i pour l'immunothérapie et le diagnostic du cancer
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
JP6034782B2 (ja) 2010-05-25 2016-11-30 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ Ｂａｍｂａｍ：ハイスループットシークエンシングデータの同時比較解析
US8340685B2 (en) 2010-08-25 2012-12-25 The Nielsen Company (Us), Llc Methods, systems and apparatus to generate market segmentation data with anonymous location data
EP3225697A3 (fr) 2010-12-30 2017-11-22 Foundation Medicine, Inc. Optimisation d'une analyse multigénique d'échantillons tumoraux
WO2012159643A1 (fr) * 2011-05-24 2012-11-29 Biontech Ag Vaccins individualisés pour le cancer
LT2714071T (lt) * 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
AU2012302778B2 (en) 2011-08-31 2016-11-24 Mie University Vaccine preparation for cancer treatment
WO2013158611A1 (fr) 2012-04-16 2013-10-24 Agenus Inc. Méthodes et compositions destinées à traiter les glioblastomes
MX2014014199A (es) 2012-05-25 2015-02-12 Bayer Healthcare Llc Sistema y procedimiento de prediccion de la inmunogenicidad de un peptido.
WO2013177593A2 (fr) 2012-05-25 2013-11-28 Phosimmune, Inc. Identification d'antigènes phosphopeptidiques de cmh de classe i du cancer du sein à l'aide d'une technologie shla et de stratégies d'enrichissement complémentaires
EP2869842A1 (fr) * 2012-07-06 2015-05-13 Novartis AG Compositions immunogéniques et leurs utilisations
MX364370B (es) 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
EP2891099A4 (fr) 2012-08-28 2016-04-20 Broad Inst Inc Détection de variants dans des données de séquençage et un étalonnage
WO2014036562A2 (fr) 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Peptides cibles pour l'immunothérapie et le diagnostic
HK1212236A1 (en) 2012-09-05 2016-06-10 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
US10501801B2 (en) 2012-09-28 2019-12-10 University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2014093855A1 (fr) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Peptides cibles pour une thérapie et le diagnostic du cancer de l'ovaire
WO2014160902A1 (fr) 2013-03-27 2014-10-02 Fred Hutchinson Cancer Research Center Immuno-stimulation dirigée
AU2014251207B2 (en) 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (fr) 2013-05-10 2014-11-13 Biontech Ag Prédiction de l'immunogénicité d'épitopes de lymphocytes t
US12374421B2 (en) 2013-06-10 2025-07-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2015013461A2 (fr) 2013-07-26 2015-01-29 Sequenta, Inc. Vaccination anticancéreuse à évolution antigénique
WO2015014375A1 (fr) 2013-07-30 2015-02-05 Biontech Ag Antigènes de tumeur pour déterminer une thérapie anticancéreuse
WO2015034519A1 (fr) 2013-09-03 2015-03-12 University Of Virginia Patent Foundation Peptides cibles pour l'immunothérapie et le diagnostic
JP6740127B2 (ja) 2013-12-06 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物ワクチン用製剤
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
SG11201605432RA (en) 2014-01-02 2016-07-28 Sloan Kettering Inst Cancer Determinants of cancer response to immunotherapy
US20150315247A1 (en) 2014-05-04 2015-11-05 David Charles Binder High-affinity peptide-based anticancer vaccination to overcome tumor resistance to immunostimulatory antibodies and to identify TCRs that can be used successfully in adoptive T cell therapy
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
US20170224799A1 (en) 2014-09-10 2017-08-10 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
CA2961179A1 (fr) 2014-09-14 2016-03-17 Washington University Vaccins anticancereux personnalises, et procedes correspondants
EP3294324A1 (fr) * 2015-05-13 2018-03-21 Agenus Inc. Vaccins pour le traitement et la prévention du cancer
WO2017088080A1 (fr) 2015-11-25 2017-06-01 Natural Response S.A. Procédé d'obtention de saponines à partir de plantes

Also Published As

Publication number Publication date
MX392028B (es) 2025-03-04
SG10201912485PA (en) 2020-02-27
IL255333A0 (en) 2017-12-31
US10568948B2 (en) 2020-02-25
CA2984643A1 (fr) 2016-11-17
US20200237885A1 (en) 2020-07-30
MX2017014532A (es) 2018-02-21
WO2016183486A1 (fr) 2016-11-17
JP6925980B2 (ja) 2021-08-25
IL293135A (en) 2022-07-01
KR20180006945A (ko) 2018-01-19
AU2016260540A1 (en) 2017-11-30
HK1252873A1 (zh) 2019-06-06
AU2021202037A1 (en) 2021-04-29
EA201792501A1 (ru) 2018-10-31
IL255333B (en) 2022-06-01
US20160331821A1 (en) 2016-11-17
MX2022005291A (es) 2022-05-24
CN107847572A (zh) 2018-03-27
EP3294324A1 (fr) 2018-03-21
JP2021178854A (ja) 2021-11-18
JP2018515519A (ja) 2018-06-14
AU2016260540B2 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
IL255333A0 (en) Vaccines for the treatment and prevention of cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3359192A4 (fr) Polythérapie pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3474854A4 (fr) Associations médicamenteuses pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3353204A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3503887A4 (fr) Combinaisons pour le traitement du cancer
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l&#39;amyloïdose
EP3411073A4 (fr) Combinaisons pour le traitement du cancer